INPLASY202330007

Survival Benefits and Bleeding Risk of Anti-VEGF Agents for Renal Cell Carcinoma (RCC): A Updated Systematic Review and Meta-Analysis of Phase 2 and 3 Randomized Clinical Trials

Keywords: renal cell carcinoma (RCC); vascular endothelial growth factor (VEGF); anti-VEGF agents; survival benefits; systematic review; meta-analysis.

Download PDF - 202330007

Review Status: Ongoing